EVis Bioscience offers gene delivery solutions using extracellular vesicles, lipid nanoparticles, and hybrid systems.
EVis Bioscience has raised $873K in total funding. The most recent round was Pre-Seed. The last funding was announced in February 2026.
EVis Bioscience's investors include Capital Cell, Innosuisse.
EVis Bioscience is headquartered in Schlieren, Switzerland.
EVis Bioscience offers gene delivery solutions using extracellular vesicles, lipid nanoparticles, and hybrid systems.
EVis Bioscience is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EVis Bioscience — Funding & Investors." VCBacked, February 23, 2026, https://www.vcbacked.co/company/evis-bioscience. Accessed September 29, 2026.
VCBacked. (2026). EVis Bioscience — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/evis-bioscience
{{cite web |title=EVis Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/evis-bioscience |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated